CD274 and urothelial carcinoma: Unfortunately, PD-L1 immunohistochemistry has performed poorly in randomized phase III trials of advanced disease, which have led to withdrawal of approvals of first-line atezolizumab and pembrolizumab for PD-L1 high-expressing advanced cisplatin-ineligible urothelial carcinoma.